Unveiling the Hidden Epidemic: MASLD Prevalence in India

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease (NAFLD), is emerging as a silent health crisis across India. Characterized by excessive fat accumulation in the liver not caused by alcohol consumption, MASLD often progresses undetected until advanced stages like fibrosis or cirrhosis. Recent groundbreaking research from the Phenome India Cohort, spearheaded by the CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), has quantified this burden, revealing an alarming age-adjusted prevalence of 38.9% among Indian adults. This study underscores the urgent need for heightened awareness, early screening, and targeted interventions in a country where metabolic disorders like obesity and diabetes are surging.

The Phenome India–CSIR Health Cohort Knowledgebase (PI-CHeCK) provides the first large-scale, community-based data on MASLD using advanced diagnostic tools across diverse urban settings. By examining real-world evidence from CSIR employees, retirees, and spouses, it offers insights into how lifestyle, genetics, and regional factors interplay in this metabolic condition. For researchers and health professionals in India's higher education and scientific institutions, these findings highlight opportunities for collaborative studies and career growth in precision medicine.Explore research positions driving such discoveries.

The Phenome India Cohort: Methodology and Scope

Launched by the Council of Scientific and Industrial Research (CSIR), the Phenome India project aims to create a comprehensive health database tailored to India's diverse population. The MASLD study drew from 10,267 adults screened at 37 CSIR laboratories spanning 27 cities in 17 states and two union territories between December 2023 and June 2024. After exclusions for incomplete data or viral hepatitis, 7,764 participants were analyzed—predominantly urban, middle-income professionals with mean age of 51 years.

Diagnosis relied on non-invasive Transient Elastography via FibroScan, measuring hepatic steatosis through Controlled Attenuation Parameter (CAP >248 dB/m) alongside at least one cardiometabolic risk factor (CMRF), such as obesity (BMI ≥25 kg/m²), dysglycemia (HbA1c ≥5.7% or diabetes), hypertension, dyslipidemia, or low HDL. Fibrosis was staged by Liver Stiffness Measurement (LSM), with significant fibrosis defined as ≥8.2 kPa (F2 or higher). Trained technicians ensured quality (IQR/median <0.3), providing reliable, reproducible results without biopsies.

This rigorous protocol, detailed in the study published in The Lancet Regional Health – Southeast Asia in February 2026, sets a benchmark for future epidemiological research in Indian higher education institutions.Access the full publication CSIR-IGIB's leadership exemplifies how government-backed research hubs foster innovation, attracting talent for roles in genomics and integrative biology.

Key Prevalence Findings: Nearly 40% Burden

The crude MASLD prevalence stood at 47.8% (3,712 cases), adjusting to 38.9% (95% CI: 37.2–40.6%) for age standardization. Males showed higher rates (45.9% age-adjusted) than females (33%), reflecting sex-specific metabolic differences. Worryingly, 31.7% had three or more CMRFs, amplifying risks.

• Lean MASLD (BMI <25): 18.1% of cases, often linked to visceral fat.
• Obesity Class I (25–30 kg/m²): 44.9%.
• Obesity Class II (≥30 kg/m²): 18.3%, with exponentially higher odds (AOR 13.8).

Diabetes prevalence was 24.8%, hypertension 55%, painting a picture of intertwined metabolic syndrome. These statistics from CSIR labs nationwide emphasize the value of institutional cohorts in higher ed research.Join research assistant opportunities at similar institutes.

Regional Hotspots and Urban Variations

Prevalence varied strikingly: 27% age-adjusted in Thiruvananthapuram (lowest) to nearly 50% in Roorkee and Bhopal (highest). Metros like Bengaluru (40.6%), Chennai (41.2%), Hyderabad (40.9%), Delhi, and Pune ranged 37–42%. Northern, central, and southern regions showed elevated rates, while the North-East lagged.

Fibrosis hotspots included Assam (Jorhat), with rates up to 8.3%, suggesting dietary, genetic, or environmental influences. Central adiposity (waist-hip ratio) correlated strongly regionally, urging localized strategies. For academics studying public health disparities, this data fuels theses and grants.India higher ed jobs

Unpacking Risk Factors: Obesity Leads the Pack

Obesity emerged as the dominant driver (AOR 2.6 overweight, 5.6 Class I, 13.8 Class II), followed by diabetes (AOR 2.2), dyslipidemia (1.7), and hypertension (1.3). Postmenopausal women faced 2.6-fold risk due to fat redistribution. Cytokine profiling revealed Th1-skewed inflammation (e.g., IL-7, IL-8 doubled in fibrosis cases), linking immunity to progression.

Step-by-step pathogenesis: Excess calories deposit triglycerides in hepatocytes → insulin resistance → lipotoxicity → inflammation → fibrosis. In India, urban diets high in refined carbs exacerbate this, contrasting rural patterns. Researchers at CSIR-IGIB decoded these via multi-omics, inspiring careers in metabolic research.Clinical research jobs

Liver Fibrosis: The Progression Alarm

Significant fibrosis (≥F2) affected 2.4% overall (age-adjusted), rising to 4.1% in MASLD (6.3% crude). It clustered in those over 60 (AOR 4.8–5), diabetics (9.1%), and obese Class II (8.1%). Even without MASLD, 1.7% had fibrosis, hinting other causes.

• Early fibrosis (F2): Prevalent across ages but surges post-50.
• Cirrhosis (F4, LSM ≥13.6 kPa): Mostly >60 years.
• Male predominance at all stages.

FibroScan's scalability makes it ideal for campus health programs in universities. This underscores training needs for higher ed in non-invasive diagnostics.Academic CV tips

Public Health Implications and Policy Calls

With 38.9% prevalence, MASLD strains India's healthcare amid rising diabetes (projected 134 million by 2045). Hotspots demand targeted screening; integrate TE into NCD programs. Community awareness via CSIR networks can prevent progression—lifestyle mods reverse early steatosis 70–80% of cases.

Stakeholders: ICMR, MoHFW should fund longitudinal follow-ups. Balanced views: Optimism in reversible early stages, caution on fibrosis irreversibility. For India's research ecosystem, this boosts funding for hepatology.AI in Indian research

CSIR-IGIB's Pivotal Role in Indian Research Landscape

CSIR-IGIB, affiliated with Academy of Scientific and Innovative Research (AcSIR), led via consortium including IICB Kolkata. Lead authors Meghana Arvind, Anshul Verma; correspondents Kumardeep Chaudhary, Shantanu Sengupta. This publication exemplifies CSIR's phenomics push, generating jobs in bioinformatics, epidemiology.

Higher ed implications: Boosts PhD intakes, postdocs in genomics. AcSIR campuses train next-gen scientists tackling metabolic epidemics. Explore postdoc openings or professor roles in similar fields.

Future Outlook: Precision Medicine and Longitudinal Tracking

PI-CHeCK's multi-modal follow-up (genomics, proteomics) promises biomarkers, e.g., cytokine panels for fibrosis risk. Longitudinal data will track interventions' efficacy. Challenges: Rural extrapolation, alcohol confounders. Solutions: Scale TE nationally, AI for risk prediction.

Optimistic horizon: India's research boom (3rd globally) positions it for MASLD cures. Students, pursue hepatology via scholarships.

Photo by Gayatri Malhotra on Unsplash

Actionable Insights for Prevention and Early Detection

• Maintain BMI <25 via balanced Indian diets (millets, veggies).
• Screen high-risk: Diabetics, obese—annual LSM.
• Exercise 150 min/week reduces steatosis 30%.
• Monitor HbA1c, lipids routinely.

Universities: Implement wellness programs. Professionals: Leverage Rate My Professor for mentors in health sciences.